权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Angiogenesis Inhibition: Targeting the MAP-2 enzyme

血管生成抑制：针对 MAP-2 酶

基本信息

批准号：
6549495
负责人：
JAMES BIGELOW
金额：
$ 10万
依托单位：
BIOMES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2002
资助国家：
美国
起止时间：
2002-09-18 至 2004-02-17
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6549495
关键词：
aminopeptidase angiogenesis inhibitors bioassay biological products drug discovery /isolation enzyme inhibitors high performance liquid chromatography methionine microorganism population study soil microbiology

项目摘要

DESCRIPTION (provided by applicant): Angiogenesis is a necessary process for continued tumor growth and provides a convenient method for tumor metastasis. Tumors utilize the host's vascular system to direct new blood vessel formation from the host to the tumor. The process requires endothelial cell division and endothelial cell migration from the existing blood vessel to the tumor mass. Over the past several years, processes critical to angiogenesis have been identified. One of these is the enzyme methionine aminopeptidase 2 (MAP-2), an enzyme pivotal in endothelial cell division. Others have described small molecules capable of inhibiting this enzyme and preventing tumor angiogenesis in experimental systems. These molecules are all microbially derived. The goal of our research is to assess the ability of our novel sources of microbes- the deep subsurface of the Earth- for their ability to produce small molecule that inhibit MAP-2 and then develop these molecules into clinical entities. To accomplish this goal we have developed a progressive, interactive bioassay-chemical isolation protocol that will enable us to effectively identify and prioritize molecules for continued pre-clinical and clinical development. The goal of the Phase 1 grant is to provide proof of principle that our unique microbes produce such molecules and that we can isolate such molecules from microbial broths in sufficient quantities to perform continued drug discovery activities in Phase 2 studies. PROPOSED COMMERCIAL APPLICATION: Cancer is the number 2 killer of Americans. Metastasis is the primary cause of death in cancer. The development of an effective anti-angiogenesis drug would have a dramatic effect on our ability to treat and control cancer. The market would be immense.

描述（由申请人提供）：血管生成是肿瘤持续生长的必要过程，并为肿瘤转移提供了方便的方法。肿瘤利用宿主的血管系统将新血管形成从宿主引导至肿瘤。该过程需要内皮细胞分裂和内皮细胞从现有血管迁移到肿瘤块。在过去的几年中，已经确定了血管生成的关键过程。其中之一是甲硫氨酸氨肽酶2（MAP-2），一种在内皮细胞分裂中起关键作用的酶。其他人已经描述了能够在实验系统中抑制这种酶并防止肿瘤血管生成的小分子。这些分子都来自微生物。我们研究的目标是评估我们的新微生物来源-地球深层地下-产生抑制MAP-2的小分子的能力，然后将这些分子开发成临床实体。为了实现这一目标，我们开发了一种先进的、交互式的生物测定-化学分离方案，使我们能够有效地识别和优先考虑分子，以进行持续的临床前和临床开发。第一阶段资助的目标是提供原则证明，即我们独特的微生物产生这样的分子，并且我们可以从微生物肉汤中分离出足够数量的这样的分子，以在第二阶段研究中继续进行药物发现活动。建议的商业应用：癌症是美国人的第二大杀手。转移是癌症死亡的主要原因。开发一种有效的抗血管生成药物将对我们治疗和控制癌症的能力产生巨大影响。市场将是巨大的。